Full text is available at the source.
Abstract
A next-generation agonist is being developed for longer-acting effects and enhanced clinical benefits.
- The new agonist aims to provide sustained efficacy over a longer period.
- Improved tolerability is a key focus of the development process.
- This agonist may offer advantages compared to existing treatments.
- Potential benefits include better management of symptoms.
Simplified